The team of Simon Yates have stated that the rider’s positive test arose due to an error by the team doctor in failing to apply for a Therapeutic Use Exemption (TUE).
News emerged yesterday evening that a British rider had tested positive in an in-competition test in France last month and it was later confirmed that the rider in question is Simon Yates.
The statement from ORICA-GreenEDGE confirmed that the British rider’s positive result is for the substance Terbutaline.
The statement from ORICA-GreenEDGE is as follows:
On April 22, the team was notified that Simon Yates has an adverse analytical finding from a test conducted at Paris-Nice, stage 6 on March 12, 2016.
The positive result is for the substance Terbutaline.
The substance was given to Simon Yates in the form an asthma inhaler and accordingly, this was noted by the team doctor on the Doping Control Form, signed at the time of the test.
The substance was given in an ongoing treatment of Simon Yates’ documented asthma problems. However, in this case the team doctor made an administrative error by failing to apply for the TUE required for the use of this treatment.
The use of Terbutaline without a current TUE is the reason it has been flagged as an adverse analytical finding. This is solely based on a human error that the doctor in question has taken full responsibility for.
There has been no wrong-doing on Simon Yates’ part. The team takes full responsibility for this mistake and wishes to underline their support for Simon during this process.
The team is concerned by the leak of this information and has no further comments until there has been a full evaluation made of the documentation, statements and evidence that the team and Simon Yates are now submitting to the UCI in order to clarify everything.